ULTI — Ultimovacs ASA Share Price
- NOK285.91m
- NOK20.07m
Growth & Value
12m Forecast Rolling | Industry | Market | |
---|---|---|---|
PE Ratio (f) | 0.81 | ||
PEG Ratio (f) | 0.01 | ||
EPS Growth (f) | 791.42% | ||
Dividend Yield (f) | n/a |
Valuation (ttm) | Industry | Market | |
---|---|---|---|
Price to Book Value | 1.02 | ||
Price to Tang. Book | 1.39 | ||
Price to Free Cashflow | n/a | ||
Price to Sales | n/a | ||
EV to EBITDA | n/a |
Shareholder Activity
Type | Buy / Hold / Sell |
---|---|
Institutions | |
Directors | |
Community |
Guru Screens
Quality
Name | Industry | Market | |
---|---|---|---|
Return on Capital | -73.65% | ||
Return on Equity | -51.94% | ||
Operating Margin | n/a |
Financial Summary
Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
---|---|---|---|---|---|---|---|---|---|
Total Revenue | NOKm | n/a | n/a | n/a | n/a | n/a | 953.5 | n/a | n/a |
Operating Profit | m | ||||||||
Net Profit | m | ||||||||
EPS Reported | |||||||||
Diluted Normalised EPS | |||||||||
EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
PE Ratio | x | ||||||||
PEG | |||||||||
Profitability | |||||||||
Operating Margin | % | ||||||||
ROA | % | ||||||||
ROCE | % | ||||||||
ROE | % | ||||||||
Cashflow | |||||||||
Op. Cashflow ps | |||||||||
Capex ps | |||||||||
Free Cashflow ps | |||||||||
Dividends | |||||||||
Dividend ps | |||||||||
Dividend Growth | % | ||||||||
Dividend Yield | % | ||||||||
Dividend Cover | x | ||||||||
Balance Sheet | |||||||||
Cash etc | m | ||||||||
Working Capital | m | ||||||||
NFA | m | ||||||||
Net Debt | m | ||||||||
Book Value | m | ||||||||
Diluted Weighted Average Shares | m | ||||||||
Book Value ps |
Other Ratios
Leverage (ttm) | Total | - Intang | + Pension |
---|---|---|---|
Gross Gearing | |||
Net Gearing | |||
Cash / Assets |
Liquidity (ttm) | |
---|---|
Curr. Ratio | |
Quick Ratio | |
Interest Cov. |
Efficiency (ttm) | |
---|---|
Asset Turnover | |
Recs Turnover | |
Stock Turnover |
Recent History
Latest interim period vs. prior period | Industry | Market | |
---|---|---|---|
Sales Growth | |||
EPS Growth |
3yr Compound Annual Growth Rate | Industry | Market | |
---|---|---|---|
Sales CAGR | |||
EPS CAGR | |||
DPS CAGR |
Profile Summary
Ultimovacs ASA is a Norway-based pharmaceutical company developing immunotherapies against cancer. Ultimovacs’ technology is based on preclinical and clinical research on immunotherapies conducted at the Oslo University Hospital. Ultimovacs is advancing a broad clinical development program with clinical trials in Europe, Australia and the U.S. The Company's lead product candidate is UV1, a peptide-based vaccine inducing a specific T cell response against the universal cancer antigen telomerase. UV1 is being developed as a therapeutic cancer vaccine which may serve as a platform for use in combination with other immuno-oncology drugs which require an ongoing T cell response for their mode of action.
Directors
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- March 29th, 2011
- Public Since
- June 3rd, 2019
- No. of Employees
- 27
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Oslo Stock Exchange
- Shares in Issue
- 34,406,061
- Address
- Ullernchausseen 64, OSLO, 0379
- Web
- https://ultimovacs.com/
- Phone
- Auditors
- Ernst & Young AS
Upcoming Events for ULTI
Q2 2024 Ultimovacs ASA Earnings Release
Similar to ULTI
Arcticzymes Technologies ASA
Oslo Stock Exchange
Bergenbio ASA
Oslo Stock Exchange
Circio Holding ASA
Oslo Stock Exchange
Exact Therapeutics AS
Oslo Stock Exchange
Lifecare AS
Oslo Stock Exchange
FAQ
As of Today at 19:23 UTC, shares in Ultimovacs ASA are trading at NOK8.31. This share price information is delayed by 15 minutes.
Shares in Ultimovacs ASA last closed at NOK8.31 and the price had moved by -93.6% over the past 365 days. In terms of relative price strength the Ultimovacs ASA share price has underperformed the FTSE Global All Cap Index by -93.99% over the past year.
The overall consensus recommendation for Ultimovacs ASA is Strong Sell. You can view the full broker recommendation list by unlocking its StockReport.
Ultimovacs ASA does not currently pay a dividend.
Ultimovacs ASA does not currently pay a dividend.
Ultimovacs ASA does not currently pay a dividend.
To buy shares in Ultimovacs ASA you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of NOK8.31, shares in Ultimovacs ASA had a market capitalisation of NOK285.91m.
Here are the trading details for Ultimovacs ASA:
- Country of listing: Norway
- Exchange: OSL
- Ticker Symbol: ULTI
Based on an overall assessment of its quality, value and momentum Ultimovacs ASA is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Ultimovacs ASA is NOK79.50. That is 856.68% above the last closing price of NOK8.31.
Analysts covering Ultimovacs ASA currently have a consensus Earnings Per Share (EPS) forecast of NOK16.36 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Ultimovacs ASA. Over the past six months, its share price has underperformed the FTSE Global All Cap Index by -95.11%.
As of the last closing price of NOK8.31, shares in Ultimovacs ASA were trading -90.9% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Ultimovacs ASA PE ratio based on its reported earnings over the past 12 months is 0.81. The shares last closed at NOK8.31.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on Ultimovacs ASA's directors